Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M

Cryoport, Inc.

2025-Q3 EPS reported $1.68 revenue$130,727,000

Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.
Commercial Cell & Gene Therapy revenue up 36% YoY to $8.3M; supported 19 commercial therapies.
GAAP net loss attributable to common stockholders $8.9M ($0.18 loss per share) in Q3.
Adjusted EBITDA from continuing ops improved to -$0.6M from -$2.7M; cash/investments $421.3M.
Full-year 2025 revenue guidance raised to $170M-$174M from continuing operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.